Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5
The European Medicines Agency (EMA) is to reviewSamsung Bioepis’ Marketing Authorisation Application (MAA) for SB5.
Click on this link for more information.
top of page
bottom of page